• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Cook Zenith移植物植入术后腹主动脉瘤瘤囊行为:212例患者的五年随访评估

Abdominal aortic aneurysm sac behavior following Cook Zenith graft implantation: a five-year follow-up assessment of 212 cases.

作者信息

Becquemin J P, Aksoy M, Marzelle J, Roudot-Thoraval F, Desgranges P, Allaire E, Kobeiter H

机构信息

Department of Vascular Surgery, Henri Mondor Hospital, University Paris XII, Creteil, France.

出版信息

J Cardiovasc Surg (Torino). 2008 Apr;49(2):199-206.

PMID:18431340
Abstract

AIM

Aneurysm shrinkage is an expected outcome after stent-grafting for abdominal aortic aneurysm (AAA). A worrying problem following repair is progressive enlargement indicating persistent sac pressurization: in this setting not all grafts are equal. The Cook Zenith device (CZ) became available on the European market in 1999. While multicenter studies on the device have shown favorable clinical results at mid-term follow-up, few have focused on sac behavior. This study evaluated AAA sac behavior and predictive factors of its evolution by assessing the five-year results obtained with the CZ graft in a single-institution experience.

METHODS

All consecutive elective surgery patients treated with a CZ graft for infrarenal aortic or aortoiliac aneurysm repair from January 2000 to November 2004 in our institution were included prospectively in the study and followed at 1, 6, 12, 18, 24 months and yearly thereafter. Pre-, intra- and postoperative data were recorded in a computerized database. Computed tomography (CT) scans were reviewed by a senior radiologist to identify any abnormalities including endoleak and graft malfunction. Pre- and postoperative maximum sac diameters were derived from measurements of CT findings and then compared. A change of at least 8 mm in sac size was considered significant. Overall results are expressed according to the Committee on Reporting Standards of AAA treatment. Factors that may have influenced sac behavior were analyzed by dividing the patients into 3 groups according to whether the sac diameter remained unchanged (group 1), had increased (group 2) or regressed (group 3). Statistical analysis of the demographic and CT-scan data was then performed.

RESULTS

The study sample was 212 consecutive patients (mean age 72.8+/-9.0 years); the mean aneurysm diameter before treatment was 55.5+/-9.8 mm. All stent grafts were successfully implanted. The 30-day mortality rate was 0.94% (2/212); the morbidity rate was 11.7% (25/212). The primary technical success rate was 93.40%; the assisted primary technical success and secondary technical success rates were 96.63% and 99.52%, respectively. The mean follow-up period was 17.7+/-14.7 (1-60) months. The cumulative survival probability was 94%, 84.2%, and 72.9% at 12, 24, and 36 months, respectively. The endoleak-free survival probabilities at 12 and 24 months were 75.7% and 62.8%, respectively. The free of intervention survival rates were 82.1%, 68.9% and 60.6% at 12, 24 and 38 months, respectively. At five years follow-up, the overall clinical success rate was 49.5%. If changes in sac diameter occurred, they were noted at 13 months on average. Sac size remained unchanged in 115 (54.3%) patients (group 1), increased in 9 (4.2%) (group 2), and regressed in 88 (41.5%) (group 3). Neither preoperative patient demographics nor aneurysm characteristics were found to be predictive of sac behavior. Aortouniliac graft configuration was predictive of sac shrinkage (P=0.020). Endoleak was more frequent among patients in groups 1 (27/115; 23%) and 2 (5/9; 56%) than among those in group 3 (9/88;10%) (P=0.001). Reduction in aneurysm sac diameter was less marked in patients with any type of endoleak (P=0.0003).

CONCLUSION

The CZ grafts offered satisfactory overall results up to five years of follow-up; nevertheless, sac diameter increased in 4.25% of patients. Endoleak was a predictive factor of a lack of sac shrinkage, while aortouniliac graft configuration was predictive of sac shrinkage.

摘要

目的

腹主动脉瘤(AAA)腔内修复术后瘤体缩小是预期的结果。修复术后一个令人担忧的问题是瘤体持续增大,提示瘤腔内仍有压力:在这种情况下,并非所有的移植物效果都相同。Cook Zenith装置(CZ)于1999年进入欧洲市场。虽然关于该装置的多中心研究在中期随访时显示了良好的临床效果,但很少有研究关注瘤腔的变化情况。本研究通过评估单中心使用CZ移植物获得的五年结果,来评价AAA瘤腔变化情况及其演变的预测因素。

方法

2000年1月至2004年11月期间,在本机构接受CZ移植物治疗肾下腹主动脉瘤或主-髂动脉瘤的所有连续择期手术患者均被前瞻性纳入本研究,并在术后1、6、12、18、24个月及之后每年进行随访。术前、术中和术后数据均记录在计算机数据库中。由一位资深放射科医生复查计算机断层扫描(CT)图像,以识别任何异常情况,包括内漏和移植物故障。术前和术后瘤腔最大直径通过测量CT结果得出,然后进行比较。瘤腔大小至少改变8mm被认为有显著意义。总体结果根据AAA治疗报告标准委员会的标准进行表述。根据瘤腔直径是否保持不变(第1组)、增大(第2组)或缩小(第3组),将患者分为3组,分析可能影响瘤腔变化的因素。然后对人口统计学和CT扫描数据进行统计分析。

结果

研究样本为212例连续患者(平均年龄72.8±9.0岁);治疗前动脉瘤平均直径为55.5±9.8mm。所有支架型人工血管均成功植入。30天死亡率为0.94%(2/212);发病率为11.7%(25/212)。主要技术成功率为93.40%;辅助主要技术成功率和次要技术成功率分别为96.63%和99.52%。平均随访期为17.7±14.7(1 - 60)个月。12、24和36个月时的累积生存概率分别为94%、84.2%和72.9%。12个月和24个月时无内漏生存概率分别为75.7%和62.8%。12、24和38个月时无需干预生存率分别为82.1%、68.9%和60.6%。在五年随访时,总体临床成功率为49.5%。如果瘤腔直径发生变化,平均在13个月时被发现。115例(54.3%)患者瘤腔大小保持不变(第1组),9例(4.2%)增大(第2组),88例(41.5%)缩小(第3组)。术前患者人口统计学特征和动脉瘤特征均未发现可预测瘤腔变化情况。主-髂移植物构型可预测瘤腔缩小(P = 0.020)。第1组(27/115;23%)和第2组(5/9;56%)患者的内漏发生率高于第3组(9/88;10%)(P = 0.001)。任何类型内漏的患者,动脉瘤瘤腔直径缩小均不明显(P = 0.0003)。

结论

CZ移植物在长达五年的随访中总体结果令人满意;然而,4.25%的患者瘤腔直径增大。内漏是瘤腔缺乏缩小的预测因素,而主-髂移植物构型是瘤腔缩小的预测因素。

相似文献

1
Abdominal aortic aneurysm sac behavior following Cook Zenith graft implantation: a five-year follow-up assessment of 212 cases.Cook Zenith移植物植入术后腹主动脉瘤瘤囊行为:212例患者的五年随访评估
J Cardiovasc Surg (Torino). 2008 Apr;49(2):199-206.
2
Midterm clinical success and behavior of the aneurysm sac after endovascular AAA repair with the Excluder graft.使用Excluder移植物进行血管内腹主动脉瘤修复术后的中期临床成功率及瘤囊情况
J Vasc Surg. 2005 Dec;42(6):1052-7. doi: 10.1016/j.jvs.2005.05.009.
3
Multicenter pivotal trial results of the Lifepath System for endovascular aortic aneurysm repair.用于血管内主动脉瘤修复的Lifepath系统的多中心关键试验结果。
J Vasc Surg. 2004 Jan;39(1):34-43. doi: 10.1016/j.jvs.2003.10.036.
4
Redefining postoperative surveillance after endovascular aneurysm repair: recommendations based on 5-year follow-up in the US Zenith multicenter trial.血管内动脉瘤修复术后再定义术后监测:基于美国Zenith多中心试验5年随访结果的建议
J Vasc Surg. 2008 Aug;48(2):278-84; discussion 284-5. doi: 10.1016/j.jvs.2008.02.075. Epub 2008 Jun 24.
5
Treatment of sac expansion after endovascular aneurysm repair with obliterating endoaneurysmorrhaphy and stent graft preservation.采用闭塞性动脉瘤缝合法及保留支架型人工血管治疗血管内动脉瘤修复术后的瘤体扩张。
J Vasc Surg. 2016 Apr;63(4):902-8. doi: 10.1016/j.jvs.2015.10.059. Epub 2015 Nov 21.
6
Variable sac behavior after endovascular repair of abdominal aortic aneurysm: analysis of core laboratory data.腹主动脉瘤血管腔内修复术后的可变囊状表现:核心实验室数据分析
J Vasc Surg. 2004 Jan;39(1):95-101. doi: 10.1016/j.jvs.2003.08.009.
7
Long-term outcome after Talent endograft implantation for aneurysms of the abdominal aorta: a multicenter retrospective study.Talent 血管内移植物植入治疗腹主动脉瘤的长期疗效:一项多中心回顾性研究
J Vasc Surg. 2006 Feb;43(2):277-84; discussion 284. doi: 10.1016/j.jvs.2005.09.037.
8
Outcomes of secondary interventions after abdominal aortic aneurysm endovascular repair.腹主动脉瘤血管腔内修复术后二次干预的结果
J Vasc Surg. 2004 Feb;39(2):298-305. doi: 10.1016/j.jvs.2003.09.043.
9
Results of endovascular repair of infrarenal aortic aneurysms using the Endurant stent graft.使用 Endurant 支架移植物进行腹主动脉瘤的血管内修复的结果。
J Vasc Surg. 2014 May;59(5):1195-202. doi: 10.1016/j.jvs.2013.12.031. Epub 2014 Jan 14.
10
Sac behavior after aneurysm treatment with the Gore Excluder low-permeability aortic endoprosthesis: 12-month comparison to the original Excluder device.使用戈尔低渗透率主动脉覆膜支架系统治疗动脉瘤后的瘤囊情况:与第一代戈尔覆膜支架系统的12个月对比研究
J Vasc Surg. 2006 Oct;44(4):694-700. doi: 10.1016/j.jvs.2006.06.018. Epub 2006 Aug 22.